Hansa Biopharma AB (publ) (HNSBF)
USD 2.83
(0.0%)
USD 2.83
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -788.49 Million SEK | -34.37% |
| 2022 | -588.58 Million SEK | -7.61% |
| 2021 | -546.97 Million SEK | -29.37% |
| 2020 | -422.8 Million SEK | -17.55% |
| 2019 | -359.66 Million SEK | -45.91% |
| 2018 | -246.49 Million SEK | -39.99% |
| 2017 | -176.08 Million SEK | -58.44% |
| 2016 | -111.13 Million SEK | -67.88% |
| 2015 | -66.2 Million SEK | -167.92% |
| 2014 | -24.7 Million SEK | -40.08% |
| 2013 | -17.63 Million SEK | -4.95% |
| 2012 | -16.8 Million SEK | -168.7% |
| 2011 | 24.46 Million SEK | 222.37% |
| 2010 | -19.99 Million SEK | -27.01% |
| 2009 | -15.74 Million SEK | 1.04% |
| 2008 | -15.9 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -152.89 Million SEK | 15.97% |
| 2024 Q3 | -116.92 Million SEK | 35.64% |
| 2024 Q2 | -181.67 Million SEK | -18.83% |
| 2023 Q3 | -202.15 Million SEK | 11.51% |
| 2023 Q4 | -181.95 Million SEK | 9.99% |
| 2023 FY | -790.87 Million SEK | -34.37% |
| 2023 Q1 | -182.34 Million SEK | -24.69% |
| 2023 Q2 | -228.45 Million SEK | -25.28% |
| 2022 FY | -588.58 Million SEK | -7.61% |
| 2022 Q2 | -167.83 Million SEK | -24.3% |
| 2022 Q3 | -139.49 Million SEK | 16.89% |
| 2022 Q4 | -146.24 Million SEK | -4.84% |
| 2022 Q1 | -135.02 Million SEK | 17.04% |
| 2021 FY | -546.97 Million SEK | -29.37% |
| 2021 Q4 | -162.75 Million SEK | -9.84% |
| 2021 Q3 | -148.17 Million SEK | -11.95% |
| 2021 Q2 | -132.35 Million SEK | -27.65% |
| 2021 Q1 | -103.68 Million SEK | 2.35% |
| 2020 Q1 | -91.35 Million SEK | 17.04% |
| 2020 FY | -422.8 Million SEK | -17.55% |
| 2020 Q3 | -123.44 Million SEK | -21.23% |
| 2020 Q2 | -101.82 Million SEK | -11.47% |
| 2020 Q4 | -106.18 Million SEK | 13.98% |
| 2019 Q4 | -110.11 Million SEK | -18.16% |
| 2019 FY | -359.66 Million SEK | -45.91% |
| 2019 Q1 | -72.68 Million SEK | 9.83% |
| 2019 Q2 | -83.68 Million SEK | -15.14% |
| 2019 Q3 | -93.19 Million SEK | -11.36% |
| 2018 Q3 | -60.5 Million SEK | -2.95% |
| 2018 Q1 | -46.62 Million SEK | 4.7% |
| 2018 Q2 | -58.76 Million SEK | -26.05% |
| 2018 FY | -246.49 Million SEK | -39.99% |
| 2018 Q4 | -80.6 Million SEK | -33.22% |
| 2017 Q3 | -37.43 Million SEK | 16.63% |
| 2017 Q4 | -48.92 Million SEK | -30.69% |
| 2017 FY | -176.08 Million SEK | -58.44% |
| 2017 Q1 | -44.82 Million SEK | -33.56% |
| 2017 Q2 | -44.9 Million SEK | -0.17% |
| 2016 Q2 | -30.67 Million SEK | -53.79% |
| 2016 Q4 | -33.56 Million SEK | -24.52% |
| 2016 FY | -111.13 Million SEK | -67.88% |
| 2016 Q3 | -26.95 Million SEK | 12.13% |
| 2016 Q1 | -19.94 Million SEK | -4.49% |
| 2015 FY | -66.2 Million SEK | -167.92% |
| 2015 Q4 | -19.08 Million SEK | -37.06% |
| 2015 Q3 | -13.92 Million SEK | 38.09% |
| 2015 Q2 | -22.49 Million SEK | -110.46% |
| 2015 Q1 | -10.68 Million SEK | -24.9% |
| 2014 Q2 | -4.83 Million SEK | 18.01% |
| 2014 Q4 | -8.55 Million SEK | -57.87% |
| 2014 Q1 | -5.89 Million SEK | -31.17% |
| 2014 FY | -24.7 Million SEK | -40.08% |
| 2014 Q3 | -5.42 Million SEK | -12.14% |
| 2013 FY | -17.63 Million SEK | -4.95% |
| 2013 Q2 | -4.31 Million SEK | 0.0% |
| 2013 Q3 | -4.49 Million SEK | -4.05% |
| 2013 Q4 | -4.49 Million SEK | 0.0% |
| 2012 FY | -16.8 Million SEK | -168.7% |
| 2011 FY | 24.46 Million SEK | 222.37% |
| 2010 FY | -19.99 Million SEK | -27.01% |
| 2009 FY | -15.74 Million SEK | 1.04% |
| 2008 FY | -15.9 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -998.398% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 16143.262% |
| SQZ Biotechnologies Company | -75.82 Million USD | -939.889% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -4318.087% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 1063.32% |
| Mesoblast Limited | -84.14 Million USD | -837.046% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -51232.737% |
| Genus plc | 6.4 Million USD | 12420.25% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 8193.398% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -84558.893% |
| Marizyme, Inc. | -34.08 Million USD | -2213.22% |
| ContraFect Corporation | -56.88 Million USD | -1286.025% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -9343.066% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -17211.601% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -56141.16% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -27561.605% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -28563.837% |
| MultiCell Technologies, Inc. | -722.81 USD | -109087488.716% |
| Accustem Sciences Inc. | -3.74 Million USD | -20946.658% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -1236.66% |
| EV Biologics, Inc. | -483.06 Thousand USD | -163128.737% |
| Q BioMed Inc. | -3.44 Million USD | -22784.036% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 22373.898% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -202301.622% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -29909.111% |
| Biomind Labs Inc. | -1 Million USD | -77999.609% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -16059.215% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -11760.623% |
| Skye Bioscience, Inc. | -13.67 Million USD | -5667.317% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -39593.146% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2632432.051% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -15530.859% |
| IMV Inc. | -38.67 Million USD | -1938.958% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -4868.551% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -40699.541% |
| GB Sciences, Inc. | -1.42 Million USD | -55407.99% |
| Alpha Cognition Inc. | -9.7 Million USD | -8024.134% |
| HST Global, Inc. | -140.9 Thousand USD | -559486.11% |
| CSL Limited | 3.7 Billion USD | 121.299% |
| Halberd Corporation | -75.05 Thousand USD | -1050527.582% |
| Enzolytics Inc. | -2.14 Million USD | -36594.713% |
| Resverlogix Corp. | -12.74 Million USD | -6084.767% |
| Affymax, Inc. | -15.04 Million USD | -5140.569% |
| SYBLEU INC | -149.18 Thousand USD | -528453.425% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -24787.241% |
| argenx SE | -425.04 Million USD | -85.507% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -1320.509% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -75426.437% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -49825.191% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -23057.147% |
| AVAX Technologies, Inc. | 6.69 Million USD | 11881.117% |
| Zenith Capital Corp. | -8.94 Million USD | -8716.907% |
| Genscript Biotech Corporation | -415.79 Million USD | -89.638% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -4526023.644% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -32013.817% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -459638.858% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -1334.35% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -27077.803% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -80027.392% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -42192.893% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -62678.344% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -39231.251% |
| BioStem Technologies, Inc. | -7.77 Million USD | -10036.253% |
| ONE Bio Corp. | 13.68 Million USD | 5863.207% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -434368.964% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -58944.309% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -69994.39% |
| Agentix Corp. | -1.37 Million USD | -57380.776% |
| LadRx Corporation | -3.82 Million USD | -20521.682% |
| Cell Source, Inc. | -4.32 Million USD | -18129.663% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -189679.989% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -114682.153% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -114682.153% |
| NovAccess Global Inc. | -2.46 Million USD | -31864.845% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -26908.43% |
| Itoco Inc. | -919.14 Thousand USD | -85686.278% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -18503.563% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -70364.343% |
| Kadimastem Ltd | -3.04 Million USD | -25835.236% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -301167.738% |
| CytoDyn Inc. | -18.05 Million USD | -4266.464% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -3132581.764% |
| Mobile Lads Corp. | -554.55 Thousand USD | -142086.638% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -358180.246% |
| Qrons Inc. | -643.67 Thousand USD | -122398.707% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -139525.268% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -35260.484% |
| Rebus Holdings, Inc. | -664 Thousand USD | -118649.398% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -43311.734% |
| International Stem Cell Corporation | -663 Thousand USD | -118828.507% |
| Bioxytran, Inc. | -3.82 Million USD | -20540.462% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1497802.736% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -3876478.171% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -2074.202% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -48632.756% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -107056.632% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -25245.419% |
| Neutra Corp. | -229.48 Thousand USD | -343492.202% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -4395.673% |
| PureTech Health plc | -146.19 Million USD | -439.331% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -3568.939% |
| IXICO plc | -1.43 Million USD | -54770.981% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -8207.828% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -547.338% |
| CSL Limited | 3.81 Billion USD | 120.685% |
| Cellectis S.A. | -108.85 Million USD | -624.339% |